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Ethanol can increase the solubility of poorly soluble and hence present a higher drug concentration in the
gastrointestinal tract. This may produce a faster and more effective absorption resulting in variable and/
or high drug plasma concentrations, both of which can lead to adverse drug reactions. In this work we
therefore studied the solubility and absorption effects of nine diverse compounds when ethanol was
present. The apparent solubility was measured using the lDiss Proﬁler Plus (pION, MA) in four media
representing gastric conditions with and without ethanol. The solubility results were combined with
in-house data on solubility in intestinal ﬂuids (with and without ethanol) and pharmacokinetic param-
eters extracted from the literature and used as input in compartmental absorption simulations using
the software GI-Sim. Apparent solubility increased more than 7-fold for non-ionized compounds in sim-
ulated gastric ﬂuid containing 20% ethanol. Compounds with weak base functions (cinnarizine, dipyrid-
amole and terfenadine) were completely ionized at the studied gastric pH and their solubility was
therefore unaffected by ethanol. Compounds with low solubility in intestinal media and a pronounced
solubility increase due to ethanol in the upper gastric compartments showed an increased absorption
in the simulations. The rate of absorption of the acidic compounds indomethacin and indoprofen was
slightly increased but the extent of absorption was unaffected as the complete doses were readily
absorbed even without ethanol. This was likely due to a high apparent solubility in the intestinal com-
partment where the weak acids are ionized. The absorption of the studied non-ionizable compounds
increased when ethanol was present in the gastric and intestinal media. These results indicate that con-
comitant intake of alcohol may signiﬁcantly increase the solubility and hence, the plasma concentration
for non-ionizable, lipophilic compounds with the potential of adverse drug reactions to occur.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction relationship is described with the Henderson–Hasselbalch equa-Poor hydration as a consequence of high lipophilicity is the
main cause of the low aqueous solubility of modern drugs. In vivo,
solubility in the gastrointestinal tract is mainly a result of the pH-
gradient and presence of naturally available lipids. The stomach
has a low pH with a reported range of 1.7–3.3 (median of 2.5)
and low concentrations of lipids. In contrast, in the small intestine,
where most of the absorption occurs, the pH increases to 6.5–7.7
(median 6.9) with a bile salt and phospholipid concentration of
2.52 mM and 0.19 mM, respectively (Bergström et al., 2014). The
dissolution rate and apparent solubility (Sapp) of ionizable drugs
are dependent on their charge as a function of their dissociation
constant (pKa) and the pH of the gastrointestinal milieu. Thistion (Hasselbalch, 1916) and results in bases carrying a positive
charge in the stomach whereas acidic functions are neutral. When
emptied into the small intestine, the bases become less charged
whereas the acidic compounds typically become negatively
charged. These changes in ionization make classical acidic drugs
with a pKa < 5.5 signiﬁcantly more soluble in the small intestine
compared to the stomach. For weak bases with a pKa < 6, an
increased solubility is achieved in the gastric compartment com-
pared to the intestinal one and the compounds are at risk for pre-
cipitating when emptied from the stomach (Carlert et al., 2010;
Psachoulias et al., 2011). In early drug development platforms, sur-
rogates for gastrointestinal ﬂuids (e.g., fasted state simulated gas-
tric and intestinal ﬂuids, FaSSGF and FaSSIF, respectively) are
used to mimic the dissolution in the gastrointestinal compart-
ments (Galia et al., 1998; Vertzoni et al., 2005).
Ethanol can act as a cosolvent and increase the Sapp in gastroin-
testinal ﬂuids. This may therefore affect the absorption of poorly
Fig. 1. Potential effect of concomitant ethanol intake on solubility and subsequent absorption. Ethanol in gastrointestinal media can increase the solubility of lipophilic
compounds. As a result, the higher concentration gradient drives their absorption.
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high doses of drugs have been shown to disintegrate prematurely
and unload the complete dose in the small intestine in response
to ethanol intake (Fadda et al., 2008;Walden et al., 2007). This phe-
nomenon is referred to as dose dumping and can lead to increased
and potentially hazardous plasma concentrations and adverse side
effects of drugs with narrow therapeutic window (Lennernäs,
2009). A well-known example of this phenomenon is hydromor-
phone for which one formulation was withdrawn from the market
in 2005 after reports of ethanol-induced, dose-dumping-related,
adverse drug reactions (ADR). The withdrawn product was a cap-
sule with an extended release formulation consisting of hotmelt
extruded granules of the drug, ammonio methacrylate copolymer
type b and ethylcellulose. The latter has been shown to be sensitive
to ethanol in dissolution tests (Fadda et al., 2008). Following this
observation the FDA composed a number of substance speciﬁc
guidelines (e.g., bupropion hydrochloride, morphine sulfate and
trospium chloride) to test for ethanol sensitivity of modiﬁed release
formulations. In these guidelines dissolution behavior should be
assessed for 2 h with 0%, 5%, 20% and 40% v/v ethanol in an acidic
medium reﬂecting the gastric milieu (Anand et al., 2011).
We hypothesized that immediate release formulations of drugs
with low solubility in gastrointestinal ﬂuids may, in a similar fash-
ion as extended release formulations during dose-dumping, show
increased absorption in response to alcohol intake. This hypothesis
is based on the large drug load of such compounds which is not dis-
solved during gastrointestinal transit under normal fasted condi-
tions. If the presence of ethanol in gastrointestinal ﬂuids increases
the dissolution rate and/or the Sapp of a compound, it may also affect
the absorption proﬁle of that drug (Fig. 1). Indeed, in a previous
study investigating 22 compounds in FaSSIF, we found that non-
ionizable compounds and weak acids in particular were at a high
risk for obtaining signiﬁcantly different dissolution proﬁles when
administered with ethanol. However, ethanol is rapidly absorbed
in the intestinal tract and the impact on absorption was not
revealed in the previous study. For instance, it has been shown that
if ethanol is co-administered with water, the ethanol disappears
from the gastric compartment within 30 min and half of the dose
is emptied into the duodenum within 5 min (Levitt et al., 1997).
Other studies have shown that although the absorption of ethanol
from the small intestine is fast, it is not instantaneous, and elevated
levels of ethanol have been found in the upper small intestine up to
30 min after intake (Halsted et al., 1973). It is clear that if ethanol is
taken together with food it is diluted and the ethanol absorption is
delayed. Human in vivo studies of drug ethanol sensitivity would
require a combination of high drug doses with ethanol intake and
are not ethically feasible. In this study we therefore employed
in vitro solubility measurements and in silico absorption simula-
tions to identify compounds potentially sensitive to concomitant
ethanol intake.2. Materials and methods
2.1. Data set
Nine model compounds were included in this study on the
basis of their lipophilicity, aqueous solubility (with focus on poorly
soluble compounds), and results from a previous study of ethanol
sensitivity in FaSSIF (Fig. 2) (Fagerberg et al., 2012). The data set
included three acidic compounds (indomethacin, indoprofen and
tolfenamic acid), three non-ionizable compounds (felodipine, gris-
eofulvin and progesterone), and three weak bases (cinnarizine,
dipyridamole and terfenadine); these compounds were selected
to cover both charged and non-ionizable compounds with a diver-
sity in physicochemical properties (Table 1). Only compounds
available in their free form were included to exclude effects from
salt formation. ADMET Predictor (Simulations Plus, CA) was used
to calculate lipophilicity expressed as logP and logDpH2.5, and the
total effective permeability (Peff) for the nine compounds. Diffusiv-
ity in water was calculated according to the Stoke–Einstein’s equa-
tion on the basis of the molecular volume estimated using ACD/
Chemsketch 12.0 (Advanced Chemical Development Inc, Canada).
Pharmacokinetic parameters were gathered from the literature.
All input data used in the computational simulations are summa-
rized in Table 2.2.2. Dissolution media preparation
The composition of FaSSGF was a modiﬁcation of the gastric
medium described by Vertzoni et al. (2005). No pepsin was
included and the pH was increased from the suggested 1.6 to 2.5.
The latter was done to reﬂect recent ﬁndings regarding the pH of
human gastric-ﬂuid aspirates (Kalantzi et al., 2006; Pedersen
et al., 2013) and to avoid unnecessary wear on the stainless-steel
ﬁber-optic dip probes used for concentration determination.
A NaCl solution with pH 2.5 (NaClpH2.5) was prepared by dis-
solving 2 g NaCl in 0.9 L MilliQ water, after which the pH was
adjusted to 2.5 by the addition of HCl before adjusting the ﬁnal vol-
ume to 1 L. The resulting NaClpH2.5 was sterile-ﬁltered and stored
at 8 C. NaClpH2.5 with 20% ethanol (NaClpH2.520%Ethanol) was pre-
pared in the same fashion except that 2.5 g NaCl was used and
20% (v/v) ethanol was added to the 1 L volume (ﬁnal volume
1.2 L). The corresponding biorelevant dissolution media (BDM),
i.e. FaSSGF and FaSSGF20%Ethanol, were prepared by dissolving
6 mg SIF powder in 100 mL of each NaCl solutions.2.3. Solubility determination
Apparent solubility was determined in the four different media
using a three-channel lDiss Proﬁler Plus (pION, MA) described
Fig. 2. Chemical structures of the studied compounds.
Table 1
Physicochemical properties.a
Compound Functionb pKa logP log DpH2.5 MW (Da) Tm (C) Rotatable bonds (n)
Indomethacin a 3.91 3.5 3.5 357.8 160 3
Indoprofen a 4.02 2.5 2.5 281.3 214 3
Tolfenamic acid a 4.08 4.1 4.1 261.7 213 2
Felodipine n 4.8 4.8 384.3 143 4
Griseofulvin n 2.5 2.5 352.8 220 3
Progesterone n 3.8 3.8 314.5 128 1
Cinnarizine b 7.45 4.8 0.4 368.5 120 5
Dipyridamole b 6.20 1.6 -3.2 504.6 163 12
Terfenadine b 8.76 5.7 2.2 471.7 147 9
a Lipophilicity expressed as logP and logDpH2.5. The number of rotatable bonds was calculated with Admet Predictor 6.5 (Simulations Plus, CA); molecular weight (MW),
melting temperature (Tm) (O’Neil, 2001; Persson et al., 2013), disassociation constant (pKa) of ionizable groups at 37 C (Fagerberg et al., 2012).
b a denotes acidic, n denotes neutral and b denotes basic function.
Table 2
Pharmacokinetic properties and simulation parameters.a
Compound Max dose (mg) Diffusion coefﬁcient (109 m2/s) Density (g/mL) Peff (104 cm/s) CLPlasma (L/h) Vd (L) First pass metabolism (%)
Indomethacin 100 0.71 1.32 3.2 5.5 6.7 0
Indoprofen 200 0.79 1.31 6.1 3.2 4.0 0
Tolfenamic acid 200 0.84 1.33 4.2 9.3 10.6 20
Griseofulvin 1000 0.74 1.38 1.9 7.3 88.0 8
Felodipine 20 0.67 1.28 2.9 57.7 15.5 87
Progesterone 400 0.69 1.08 8.4 1.8 4.8 75
Cinnarizine 75 0.62 1.09 4.3 143.9 981.3 0
Dipyridamole 300 0.55 1.35 0.2 138.0 141.0 33
Terfenadine 120 0.53 1.09 5.8 12.4 12.9 b
a Diffusion coefﬁcient and density were calculated based on molecular volume, as estimated by ACD/Chemsketch 12.0 (Advanced Chemical Development Inc., Canada) and/
or molecular weight. Human effective jejunal permeability (Peff) was predicted with ADMET Predictor (Simulations Plus, CA). The plasma clearance (CLPlasma) and volume of
distribution (Vd) and compartmental parameters found in the Table A1 in Appendix A were taken from the literature (indomethacin (Obach et al., 2008), indoprofen (Tamassia
et al., 1976), tolfenamic acid (Pedersen, 1994; Pentikäinen et al., 1981), griseofulvin (Chiou and Riegelman, 1971), felodipine (Sjögren et al., 2013), progesterone (Whitehead
et al., 1980; Wright et al., 2005), cinnarizine (Shi et al., 2009) and dipyridamole (Bjornsson and Mahony, 1983)).
b Terfenadine is almost completely biotransformed into fexofenadine during ﬁrst passage metabolism; the CLPlasma and Vd of the metabolite were used in the simulations
(Garteiz et al., 1982; Lappin et al., 2010).
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with a standard curve before the dissolution assay. Estimated Sapp
was used together with chromophore strength to select dip-probe
path length. Compounds with high solubility and/or strong chro-
mophores required the use of a short-path length while a longer
one was used for compounds with weak chromophore and/or
low Sapp. Before the experiments, an approximately twofold excess
of drug powder compared to the estimated Sapp was weighed into
the vials. Preheated media (15 mL, 37 C) were added to the vials at
the start of the experiment and the temperature was held constant
at 37 ± 0.5 C. The vials were sealed using paraﬁlm to avoid evap-
oration and stirred at 100 rpm using magnetic stirrers. The exper-
iment was terminated after a stable plateau representing the Sapp
was reached but not before the 2 h period recommended by the
FDA for ethanol sensitivity testing. Interference from solid particles
of the excess powder in the vials was avoided by using the second
derivative signal from collected absorbance spectra. The resulting
dissolution proﬁles were analyzed with GraphPad Prism (Graph-
Pad Software, CA) and a nonlinear, two-phase association equation
was used to obtain the Sapp-value from the plateau. The results are
presented as mean and standard deviations (n = 3).
Lipid solubilization and the ethanol effect on Sapp at pH 2.5 were
calculated as a fold increase (the ratio) of Sapp in FaSSGF or
NaClpH2.520%Ethanol over NaClpH2.5. Ethanol effects in FaSSGF were
calculated as the ratio of Sapp in FaSSGF20%Ethanol over FaSSGF.
Standard errors (SE) for the mean fold-increase (FI) ratios were
calculated according to
SEFI ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rA2
A2
þ rB
2
B2
s
where A and B are mean Sapp in two media and rA and rB represent
the corresponding standard deviation.
2.4. Absorption simulation
In silico simulations were performed with the absorption simu-
lation software GI-Sim that has been thoroughly described else-
where (Sjögren et al., 2013). Brieﬂy, GI-Sim deploys a
compartmental physiological structure of the underlying intestinal
physiology with nine gastrointestinal (GI) compartments coupled
in series: the stomach (1), the small intestine (2–7) and the colon
(8–9) (Yu and Amidon, 1998, 1999; Yu et al., 1996). To describe
the plasma concentration–time proﬁle, the GI model is linked to
a pharmacokinetic model with up to three compartments. Physio-
logical parameters for the GI compartments previously described
were used, except that the gastric pH was somewhat elevated
and set to 2.5 in analogy with in vitro solubility measurements
(Sjögren et al., 2013). In GI-Sim, undissolved particles and dis-
solved molecules ﬂow from one GI compartment into the next.
The particles may either dissolve or grow; dissolved material
may partition into the bile salt micelles or is absorbed through
the intestinal wall. Intestinal solubility, represented by previously
reported Sapp in phosphate buffer pH 6.5 and FaSSIF (Fagerberg
et al., 2012, 2010), was used as input for the concentration in the
intestinal compartment. The pH-dependent solubility of an ioniz-
able compound is traditionally calculated in GI-Sim according to
the Henderson–Hasselbalch equation and the physiological pH in
each GI compartment. However, since the gastric solubility was
measured in this study, both gastric and intestinal in vitro values
were used as input in the simulations.
In GI-Sim, dissolution rate is described by Fick’s law together
with the Nielsen stirring model (Nielsen, 1961). Effective perme-
ability describes the absorption and total membrane transport pro-
cess that involves serial diffusion through an aqueous boundary
layer adjacent to the intestinal wall and the intestinal membrane.Absorption generally occurs in all GI compartments except the
stomach. In this study we were interested in the effect on immedi-
ate release formulations of highly permeable compounds i.e., class
2 compounds in the biopharmaceutics classiﬁcation system (BCS).
These are poorly soluble and highly permeable and therefore the
simulations only modeled absorption from the small intestinal
compartments (compartments 2–7 in GI-Sim).
Speciﬁc solubility factors, obtained from the in vitro measure-
ments, were implemented to account for the effect of ethanol on
the solubility of the investigated compounds. FaSSGF20%Ethanol and
FaSSIF20%Ethanol measurements were used for the stomach (GI com-
partment 1) and duodenum (GI compartment 2), respectively, in
simulations of concomitant intake of ethanol. The simulations used
the maximum oral doses prescribed. Two particle sizes were inves-
tigated to study their impact on the resulting dissolution. The ﬁrst
had a generic particle size with a diameter of 25 lm
(d10 = 12.5 lm, d50 = 25 lm, d90 = 50 lm). A second particle size
fraction with diameter of 5 lm (d10 = 2.5 lm, d50 = 5 lm,
d90 = 10 lm) was studied to represent micronized powder. Default
simulation time was set to 8 h. If the absorption was incomplete,
the simulation was repeated with a longer simulation time, up to
24 h, to capture the entire absorption phase. In a second step, the
simulations were repeated for compounds with a predicted 15%
increase in AUC due to the ethanol effects. These further simula-
tions were performed with ethanol only present in the stomach
to investigate if an extraordinarily rapid absorption of ethanol from
the duodenum still had the possibility to increase plasma drug
concentration.3. Results
3.1. Solubility in gastric media and ethanol effects
The low pH of the gastric media resulted in high Sapp values for
cinnarizine, dipyridamole and terfenadine as a consequence of the
complete ionization of these weak bases (Table 3). Indomethacin,
indoprofen and tolfenamic acid are weak acids with pKa val-
ues > 3.9 (Fagerberg et al., 2012); therefore at pH 2.5, they are pre-
dominantly neutral. This is reﬂected in the low Sapp in NaClpH2.5.
The Sapp of the neutral compounds – felodipine, griseofulvin and
progesterone – in the NaCl solution was also low, less than
15 lg/mL (Table 3). Only two compounds, tolfenamic acid and fel-
odipine, exhibited a higher Sapp in FaSSGF compared to NaClpH2.5
(Fig. 3a), indicating that the level of lipids present in FaSSGF was
too low to signiﬁcantly solubilize the studied compounds. All com-
pounds present in their neutral form at pH 2.5 had higher solubility
in NaClpH2.5,20%Ethanol compared to that in blank medium (Fig. 3b).
The weak basic compounds were completely charged at pH 2.5
and were unaffected by lipid aggregates, ethanol content or combi-
nation thereof. The Sapp of felodipine and tolfenamic acid was over
20 times higher in medium with lecithin, taurocholate and ethanol
than without (Fig. 3c). The remaining non-ionizable compounds
and weak acids showed 7–10-fold higher solubility in the etha-
nol-spiked FaSSGF compared to the NaCl solution. Similar trends
were observed when FaSSGF with and without ethanol were com-
pared. Here the weak bases were equally soluble in both media,
whereas neutral compounds were up to 15-fold more soluble in
ethanol containing FaSSGF (Fig. 4).3.2. Simulated absorption
Two of the model compounds with basic functions, cinnarizine
and terfenadine, were unaffected by the simulated ethanol intake
(Fig. 5). However, the absorption of dipyridamole was increased
considerably with a relative AUC increase greater than 40% and
Table 3
Experimentally determined apparent solubility at 37 C.a
Compound Apparent solubility lg/mL
NaClpH2.5 NaClpH2.520%Ethanol FaSSGF FaSSGF20%Ethanol
Indomethacin 3.0 ± 0.4 21.4 ± 1.4 1.7 ± 0.2 22.5 ± 0.5
Indoprofen 6.4 ± 0.3 39.4 ± 3.9 8.0 ± 3.0 62.4 ± 4.1
Tolfenamic acid 0.02 ± 0.01 0.11 ± 0.01 0.43 ± 0.19 0.54 ± 0.03
Felodipine 1.2 ± 0.1 29.3 ± 1.8 2.3 ± 0.4 33.1 ± 3.4
Griseofulvin 13.1 ± 1.8 116 ± 7 13.4 ± 0.4 110 ± 16
Progesterone 11.1 ± 0.3 110 ± 6 10.5 ± 0.1 104 ± 8
Cinnarizine 568 ± 54 465 ± 25 548 ± 17 526 ± 48
Dipyridamole 1258 ± 68 1710 ± 59 985 ± 5 1017 ± 31
Terfenadine 223 ± 23 412 ± 86 278 ± 11 279 ± 43
a Apparent solubility in fasted state simulated gastric ﬂuid (FaSSGF) without and with 20% ethanol (FaSSGF20%Ethanol) and corresponding media without taurocholate and
lecithin, NaClpH2.5 and NaClpH2.520%Ethanol, respectively.
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plasma peak concentration time (Tmax) decreased almost 4.5 h.
Indomethacin and indoprofen doses were according to the simula-
tions readily absorbed in both the fasted state and with concomi-
tant ethanol intake while approximately 80% of administered
tolfenamic acid was absorbed. The predicted AUC of these acidic
compounds was hence unaffected by concomitant ethanol intake.
Indomethacin and indoprofen Cmax increased slightly while the
Cmax of tolfenamic acid remained unchanged. For non-ionizable
compounds the AUC increased between 15% (griseofulvin) and
105% (felodipine) when ethanol was present in the gastric and
duodenal simulation compartments. The fraction absorbed of felo-
dipine doubled; Cmax increased almost 150% and Tmax decreased by
1 h after simulated intake of alcohol. Progesterone AUC and Cmax
increased with 17% and 16%, respectively, and Tmax decreased by
30 min as a result of the ethanol effect on Sapp.
The simulations with smaller particles (5 lm in diameter) led to
a higher fraction of the dose absorbed and/or an overall more rapid
absorption for all compounds. The changes in the plasma-concen-
tration curves observed with ethanol were not as pronounced for
the small particle size compared to the larger one (25 lm in diam-
eter). Further, the simulations in which ethanol was excluded in
the duodenal compartment showed substance-speciﬁc results. No
effect on the absorption of dipyridamole, griseofulvin and proges-
terone was observed when ethanol only was present in the gastric
compartment and hence, inﬂuenced the concentration reached in
the stomach but not in the duodenum. However, the absorption
of felodipine was still increased using this simulation protocol.4. Discussion
The main characteristic of gastric ﬂuids is their acidic pH which
has a profound effect on the solubility of ionizable compounds. The
FaSSGF used to mimic human gastric ﬂuid contains 80 lM tauro-
cholate and 20 lM lecithin, derived from soybean oil. Lecithin
has a critical micelle concentration (CMC) well below 1 nM (King
and Marsh, 1987) whereas taurocholate has a reported CMC of
6.3 mM (Yang et al., 2010). The low concentration of taurocholate
in FaSSGF in relation to its CMC implies that the bile salt may pri-
marily have wetting effects during dissolution in the medium. A
large fraction of the bile salt is likely to be dissolved in the bulk
of the medium whereas the lecithin is likely found in liposomes
together with the remainder of the taurocholate. The addition of
ethanol to aqueous systems leads to a lower dielectric constant
of the resulting mixture, which in turn leads to an increase in Sapp
of nonpolar compounds. Indeed this was conﬁrmed by our study
since drugs that were non-ionized at the studied pH (2.5) generally
had higher solubility in media containing 20% ethanol. The two
most lipophilic compounds, tolfenamic acid and felodipine, werethe compounds with the strongest positive effect on solubility by
the presence of lipids and/or ethanol. Tolfenamic acid showed a
slight increase in Sapp in media with ethanol. This was the only
compound in the study that appeared to be effectively solubilized
by the low concentrations of taurocholate and bile salt present in
FaSSGF, with a close to 20 times higher Sapp in FaSSGF compared
to that observed in the corresponding blank medium (NaClpH2.5).
This could potentially be a result of the high lipophilicity in combi-
nation with its relatively small size; tolfenamic acid had the lowest
molecular weight (261.7) of the compounds. The larger substance,
felodipine, was also solubilized by phospholipid aggregates in FaS-
SGF but its Sapp was only doubled compared to that in NaClpH2.5. On
the other hand, the effect of ethanol on felodipine Sapp was more
pronounced. The addition of 20% ethanol to NaClpH2.5 or FaSSGF
led to a 25-fold and 15-fold increase, respectively. In comparison,
the less lipophilic neutral compounds, griseofulvin and progester-
one, were both unaffected by the lipids in FaSSGF. However, they
exhibited an 8–10-fold increase in solubility after the inclusion of
20% ethanol to either NaClpH2.5 or FaSSGF. The compounds with
basic functions were highly charged and had considerably lower
lipophilicity at pH 2.5 (logDpH2.5) compared to the other drugs.
They all exhibited a relatively high Sapp due to being completely
ionized and they were therefore unaffected by either lipid content
or ethanol in the media. The observation that Sapp of uncharged and
lipophilic compounds signiﬁcantly increases in response to ethanol
is in agreement with our previous results regarding ethanol effects
in intestinal media (Fagerberg et al., 2012).
The solubility classiﬁcation in the BCS is based on dose number
(Do) which is calculated according to
Do ¼ M0
V0  Sapp
where M0 is dose and V0 is available volume (here set to 250 mL)
(Oh et al., 1993). A Do > 1 indicates that the complete dose cannot
dissolve in 250 mL of medium while a Do < 1 indicates that the dose
is soluble in this volume. None of the studied compounds obtained
an increase in Sapp due to ethanol in FaSSGF that was high enough to
cause a shift in Do when the highest prescribed dose was used for
the calculation. Cinnarizine was completely soluble in both FaSSGF
and FaSSGF20%Ethanol while all other compounds were not. If this
analysis were to be performed using a normal tablet strength rather
than the highest prescribed dose, all weak bases in this study would
have been soluble in all the media. A normal dose for felodipine
(2.5 mg) gave rise to a Do shift from above 1 in FaSSGF to below 1
after addition of 20% ethanol. Compared to our previous study on
ethanol effects on Sapp in intestinal media 20% ethanol in FaSSIF
did induce a Do shift using the max doses of felodipine and indopro-
fen. These Do shifts in FaSSIF were the result of a moderate increase
in Sapp due to 20% ethanol, with a 2- and 3-fold increase respectively
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Fig. 3. Increase in solubility as a result of mixed lipid aggregates and/or ethanol.
Fold increase over buffer due to (a) mixed lipid aggregates, (b) ethanol, and (c)
mixed lipid aggregates and ethanol in NaCl-solpH6.5. Bars represent mean fold
increase ± standard error.
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Fig. 4. Solubility increase due to 20% ethanol in FaSSGF. Bars represent mean fold
increase ± standard error.
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FaSSIF, no Do shift occurred as result of 20% ethanol for dipyridam-
ole (19-fold increase), griseofulvin (8-fold), progesterone (7-fold)
indomethacin and tolfenamic acid (3-fold). As the intestinal Sapp
of terfenadine and cinnarizine did not increase with the addition
of ethanol, neither was there any shift in Do for these compound
in the simulated intestinal ﬂuid (Fagerberg et al., 2012).
The computational simulations with GI-Sim revealed that
although the solubility of indomethacin and indoprofen was
increasedwith theadditionof20%ethanol in thegastric andduodenal
compartments, the effects on absorption were small as thecompoundswere absorbed rapidly and completely in the fasted state.
The small observed increase in Cmax is likely to be negligible. The
decrease in Tmax could indicate a potential reduction in onset due to
ethanol. This assumes however that no other parameters except the
concentrations in the stomach and intestine affect the absorption
and the resulting plasma concentration. The absorption of tolfenamic
acid and the two basic compounds terfenadine and cinnarizine was
also more or less unaffected by the simulated concomitant ethanol
intake. For the latter two the absorption was reduced slightly due to
a lower Sapp in duodenal media (FaSSIF with 20% ethanol) as a result
of suppressed ionization causedby the ethanol. Dipyridamole is com-
pletely charged at the gastric pH but only slightly so at the intestinal
pH where its Sapp is effectively increased by the addition of ethanol.
This results in a higher extent and rate of absorption predicted by
the simulations. The impact of the duodenal ethanol was revealed
when repeating thesimulationswithout ethanol in this compartment
during which the ‘ethanol’ curve was superimposed on top of the
curve without ethanol.
For the non-ionizable compounds, different plasma concentra-
tion curves were obtained when ethanol was included as compared
to the fasted state. The absorption of griseofulvin and progesterone
was slightly increased with around 15% higher values for the Fabs,
Cmax, and AUC for both compounds. The moderate increase in
absorption of griseofulvin is surprising because this compound
has been shown to exhibit strong food effects (Ogunbona et al.,
1985). Furthermore it is only slightly solubilized by lipid aggregates
(Persson et al., 2005) compared to the effect ethanol has on its Sapp
in gastric and intestinal media (Fagerberg et al., 2012). One expla-
nation for this is that the mixed lipid aggregates are present much
longer in the intestinal ﬂuid compared to the transiently elevated
levels of the rapidly absorbed ethanol. The increased absorption
of both progesterone and griseofulvin is also absent when ethanol
is only present in the gastric compartment. Felodipine however,
which is strongly affected by ethanol in both gastric and intestinal
simulated media, maintained the increased absorption when etha-
nol was only present in the gastric compartment. There are two
possible explanations for this result. First, the drug is effectively sol-
ubilized by the mixed lipid aggregates found in FaSSIF that help
maintain the high amount of dissolved substance during the gastro-
intestinal transit time. Second, the equilibrium between the sub-
stance in solution and that solubilized in aggregates is rapid,
which helps to push permeation through the gut wall.
Ethanol has previously been shown to increase the absorption
or at least plasma concentration of drugs taken concomitantly with
it. In humans, the plasma concentration of diazepam almost dou-
bles due to enhanced absorption in the presence of even a small
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Fig. 5. Plasma concentration proﬁles obtained from computational simulations. Light blue lines represent fasted conditions while dark red lines represent concomitant
ethanol intake. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 4
Simulation results.a
Compound Simulation time (h) Fasted state Concomitant ethanol intake
AUC (ng  h/mL) Cmax (ng/mL) Tmax (h) Fabs (%) AUC (ng  h/mL) Cmax (ng/mL) Tmax (h) Fabs (%)
Indomethacin 8 16,728 7824 1.2 100 16,768 8303 0.9 100
Indoprofen 8 56,202 18,371 1.0 100 56,503 20,029 0.7 100
Tolfenamic acid 8 12,181 3108 2.6 78 12,495 3146 2.5 80
Felodipine 8 6.714 1.625 2.6 15 13.77 4.011 1.6 31
Griseofulvin 24 9337 660.3 6.2 11 10,709 736.3 6.1 13
Progesterone 12 24,262 4283 3.3 44 28,494 4971 2.8 52
Cinnarizine 12 88.06 10.77 3.0 22 85.78 10.48 3.1 21
Dipyridamole 24 23.61 1.906 5.9 1.7 33.84 2.671 1.5 2.5
Terfenadine 8 5525 1575 1.4 72 5557 1590 1.4 72
a Simulation time is given in hours; increased time for griseofulvin, progesterone, cinnarizine and dipyridamole was used to allow maximal possible absorption for all
compounds. Area under the plasma concentration curve (AUC) is calculated from t = 0 to t = simulation time. Maximum plasma concentration (Cmax) represents the height of
the plasma concentration peak. Plasma maximum time (Tmax) indicates the plasma concentration peak time after simulation start. The fraction absorbed (Fabs) is the ratio
between amount dose administered and absorbed substance.
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ble BCS class I compound, it is lipophilic and neutral in intestinal
media and may thus potentially dissolve quicker and be absorbed
faster in the presence of alcohol with a higher plasma concentra-
tion peak as a result. The effects of ethanol on the in vivo absorp-
tion of acetylsalicylic acid (a soluble weak acid with pKa of 3.5
and low permeability) are ambiguous and range from negative
(Melander et al., 1995) to absent (Hollander et al., 1981) in humans
and even positive (Kato et al., 2010) in mice. A very high dose were
given to the mice (0.5 g/kg) making the cosolvent effect of ethanol
on acetylsalicylic acid solubility (Roberts et al., 2007) a possiblereason for the enhanced absorption. The now withdrawn drug pro-
poxyphene also obtained increased bioavailability when adminis-
tered with ethanol in both humans (Girre et al., 1991) and dogs
(Olsen et al., 1986); in both studies the authors attributed the
increase to altered metabolism as a result of the ethanol intake.
Ethanol ﬁrst pass metabolism occurs in the gut wall primarily by
alcohol dehydrogenases, and in the liver also through CYP2E1
(Lieber and Abittan, 1999). The latter has been shown to metabo-
lize other drugs such as theophylline and acetaminophen, and is
inhibited by disulﬁram. The ﬁndings obtained in this study support
that the increased levels of propoxyphene most likely is an effect of
Table A1
Compartmental parameters.a
Compound k12 (l/h) k21 (l/h) k13 (l/h) k31 (l/h)
Indomethacin
Indoprofen 2.5 1.9
Tolfenamic acid 0.3 0.4
Griseofulvin 0.1 0.2
Felodipine 18.2 6.9 5.0 0.8
Progesterone
Cinnarizine
Dipyridamole 5.5 1.0
Terfenadine 1.1 0.8 0.3 0.1
a The distribution rate constants k12, k21, k13 and k31 describe substance dis-
tribution between central (1) and peripheral compartments (2 and 3).
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with a pKa of 9.5 and hence, will be completely ionized in both
the gastric and intestinal compartment. Experimental results of
other such model compounds studied herein and previously
(Fagerberg et al., 2010) predict that ethanol will not increase the
solubility of propoxyphene and this factor will therefore not affect
the absorption.
Another physiological factor affected by ethanol intake is the
gastric emptying rate. Ethanol delays gastric emptying rate com-
pared to intake of e.g. water, but the extent to which seems to be
dependent on several different factors and e.g. gender (Horikoshi
et al., 2013), alcohol concentration and type of alcohol containing
beverage (Franke et al., 2004) that is ingested have been suggested
to affect emptying rate. The complex interplay between alcohol
containing beverages and gastric emptying rate made us decide
to use the fasted state gastric emptying rate deﬁned in the GI-
Sim during simulations. A delayed transport of drug from the gas-
tric compartment would likely reduce the absorption rate and
increase Tmax. On the other hand, the delay could lead to more of
the dose reaching the absorptive compartments of the small intes-
tine in solution rather than as solid particles. If so, all compounds
with high solubility in gastric media (whether because of ioniza-
tion or increased solubility with ethanol) should show increased
absorption. Indeed a large number of pharmacokinetic and phar-
macodynamic interactions between ethanol and drugs have been
reported in the literature see e.g. (Fraser, 1997; Weathermon and
Crabb, 1999). However, the focus of this study was to reveal the
effect that changes in solubility have on the resulting absorption
and for this reason, only this parameter was allowed to inﬂuence
the simulations.
The compounds selected for this study were selected as model
compounds on the basis of their diverse physicochemical proper-
ties and not that increased absorption rate would potentially lead
to serious ADRs. A signiﬁcant Sapp increase due to the presence of
ethanol in the intestinal ﬂuid does not necessarily imply that ADRs
will occur if the drugs are taken together with liquor. Instead it
should be viewed as one risk indicator among many. If the extent
or rate of absorption of a drug due to ethanol intake is paired with
a narrow therapeutic window, metabolic interactions, and/or with
synergistic pharmacodynamics effects such as respiratory depres-
sion, then the increased gastrointestinal concentration obtained
during concomitant ethanol intake may lead to potentially danger-
ous adverse side effects.5. Conclusion
In this study we explored the potential effects of concomitant
intake of ethanol on drug absorption. We focused on the effect
on solubility and measured the gastric concentration reached at
elevated ethanol levels. The data were analyzed together with pre-
vious data from simulated intestinal ﬂuids using the computa-
tional simulation tool GI-Sim. It was found that non-ionized and
lipophilic compounds were likely to have higher solubility in gas-
trointestinal ﬂuids when ethanol was present and for these, con-
comitant intake of ethanol increased the absorption. If such
compounds also have narrow therapeutic windows, the concomi-
tant ethanol intake results in a higher risk of ADRs.Acknowledgements
Financial support from The Swedish Research Council (Grants
621-2008-3777 and 621-2011-2445) and the Swedish Medical
Products Agency is gratefully acknowledged. We are also thankful
to biorelevant.com for providing the SIF original powder used in
the dissolution experiments and to Simulations Plus (Lancaster,CA) for providing the Drug Delivery group at the Department of
Pharmacy, Uppsala University, with a reference site license for
the software ADMET Predictor. We thank Elin Jern for skillful
experimental assistance with solubility measurements.
Appendix A
See Table A1.References
Anand, O., Yu, L.X., Conner, D.P., Davit, B.M., 2011. Dissolution testing for generic
drugs: an FDA perspective. AAPS J. 13, 328–335.
Bergström, C.A.S., Holm, R., Jørgensen, S.A., Andersson, S.B.E., Artursson, P., Beato, S.,
Borde, A., Box, K., Brewster, M., Dressman, J., Feng, K.-I., Halbert, G., Kostewicz,
E., McAllister, M., Muenster, U., Thinnes, J., Taylor, R., Mullertz, A., 2014. Early
pharmaceutical proﬁling to predict oral drug absorption: current status and
unmet needs. Eur. J. Pharm. Sci. 57, 173–199.
Bjornsson, T.D., Mahony, C., 1983. Clinical pharmacokinetics of dipyridamole.
Thromb. Res. 29 (Supplement 1), 93–104.
Carlert, S., Pålsson, A., Hanisch, G., Von Corswant, C., Nilsson, C., Lindfors, L.,
Lennernäs, H., Abrahamsson, B., 2010. Predicting intestinal precipitation-a case
example for a basic BCS class II drug. Pharm. Res. 27, 2119–2130.
Chiou, W.L., Riegelman, S., 1971. Absorption characteristics of solid dispersed and
micronized griseofulvin in man. J. Pharm. Sci. 60, 1376–1380.
Fadda, H.M., Mohamed, M.A.M., Basit, A.W., 2008. Impairment of the in vitro drug
release behaviour of oral modiﬁed release preparations in the presence of
alcohol. Int. J. Pharm. 360, 171–176.
Fagerberg, J.H., Al-Tikriti, Y., Ragnarsson, G., Bergström, C.A.S., 2012. Ethanol effects
on apparent solubility of poorly soluble drugs in simulated intestinal ﬂuid. Mol.
Pharm. 9, 1942–1952.
Fagerberg, J.H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., Bergström, C.A.S., 2010.
Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant
dissolution media. Mol. Pharm. 7, 1419–1430.
Franke, A., Teyssen, S., Harder, H., Singer, M.V., 2004. Effect of ethanol and some
alcoholic beverages on gastric emptying in humans. Scand. J. Gastroenterol. 39,
638–644.
Fraser, A.G., 1997. Pharmacokinetic interactions between alcohol and other drugs.
Clin. Pharmacokinet. 33, 79–90.
Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R., Reppas, C., Dressman, J.B., 1998.
Evaluation of various dissolution media for predicting in vivo performance of
class I and II drugs. Pharm. Res. 15, 698–705.
Garteiz, D.A., Hook, R.H., Walker, B.J., Okerholm, R.A., 1982. Pharmacokinetics and
biotransformation studies of terfenadine in man. Arzneim.-Forsch. 32, 1185–
1190.
Girre, C., Hirschhorn, M., Bertaux, L., Palombo, S., Dellatolas, F., Ngo, R., Moreno, M.,
Fournier, P.E., 1991. Enhancement of propoxyphene bioavailability by ethanol.
Relation to psychomotor and cognitive function in healthy volunteers. Eur. J.
Clin. Pharmacol. 41, 147–152.
Halsted, C.H., Robles, E.A., Mezey, E., 1973. Distribution of ethanol in the human
gastrointestinal tract. Am. J. Clin. Nutr. 26, 831–834.
Hasselbalch, K.A., 1916. Die Berechnung der Wasserstoffzahl des blutes auf der
freien und gebundenen Kohlensaure desselben, und die Sauerstoffbindung des
Blutes als Funktion der Wasserstoffzahl. Biochem. Z 78, 112–144.
Hayes, S.L., Pablo, G., Radomski, T., Palmer, R.F., 1977. Ethanol and oral diazepam
absorption. New Engl. J. Med. 296, 186–189.
Hollander, D., Dadufalza, V.D., Fairchild, P.A., 1981. Intestinal absorption of aspirin.
Inﬂuence of pH, taurocholate, ascorbate, and ethanol. J. Lab. Clin. Med. 98, 591–
598.
Horikoshi, M., Funakoshi, A., Miyasaka, K., Sekime, A., 2013. Sex difference in the
effects of alcohol on gastric emptying in healthy volunteers: a study using the
13C breath test. Biomed. Res. 34, 275–280.
20 J.H. Fagerberg et al. / European Journal of Pharmaceutical Sciences 67 (2015) 12–20Kalantzi, L., Goumas, K., Kalioras, V., Abrahamsson, B., Dressman, J.B., Reppas, C.,
2006. Characterization of the human upper gastrointestinal contents under
conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23,
165–176.
Kato, H., Yoshimoto, K., Kobayashi, M., Sakabe, M., Funaki, H., Ikegaya, H., 2010. Oral
administration of ethanol with aspirin increases the concentration of salicylic
acid in plasma and organs, especially the brain, in mice. Eur. J. Pharmacol. 635,
184–187.
King, M.D., Marsh, D., 1987. Head group and chain length dependence of
phospholipid self-assembly studied by spin-label electron spin resonance.
Biochemistry 26, 1224–1231.
Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R.J., Gesson, C., Houston, B.,
Oosterhuis, B., Bjerrum, O.J., Rowland, M., Garner, C., 2010. Pharmacokinetics of
fexofenadine: evaluation of a microdose and assessment of absolute oral
bioavailability. Eur. J. Pharm. Sci. 40, 125–131.
Lennernäs, H., 2009. Ethanol-drug absorption interaction: potential for a signiﬁcant
effect on the plasma pharmacokinetics of ethanol vulnerable formulations. Mol.
Pharm. 6, 1429–1440.
Levitt, M.D., Li, R., Demaster, E.G., Elson, M., Furne, J., Levitt, D.G., 1997. Use of
measurements of ethanol absorption from stomach and intestine to assess
human ethanol metabolism. Am. J. Physiol. – Gastrointestinal Liver Physiol. 273,
G951–G957.
Lieber, C.S., Abittan, C.S., 1999. Pharmacology and metabolism of alcohol, including
its metabolic effects and interactions with other drugs. Clin. Dermatol. 17, 365–
379.
Melander, O., Liden, A., Melander, A., 1995. Pharmacokinetic interactions of alcohol
and acetylsalicylic acid. Eur. J. Clin. Pharmacol. 48, 151–153.
Nielsen, A.E., 1961. Diffusion controlled growth of a moving sphere. The kinetics of
crystal growth in potassium perchlorate precipitation. J. Phys. Chem. 65, 46–49.
O’Neil, M.J., 2001. The Merck Index, 13th ed. Merck & Co Inc, Whitehouse Station,
NJ.
Obach, R.S., Lombardo, F., Waters, N.J., 2008. Trend analysis of a database of
intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug Metab. Dispos. 36, 1385–1405.
Ogunbona, F.A., Smith, I.F., Olawoye, O.S., 1985. Fat content of meals and
bioavailability of griseofulvin in man. J. Pharm. Pharmacol. 37, 283–284.
Oh, D.-M., Curl, R., Amidon, G., 1993. Estimating the fraction dose absorbed from
suspensions of poorly soluble compounds in humans: a mathematical model.
Pharm. Res. 10, 264–270.
Olsen, H., Aune, H., Lilleaasen, P., Gulliksen, M., Bodd, E., Mørland, J., 1986. The effect
of ethanol intake on propoxyphene absorption and biotransformation in dogs.
Alcohol.: Clin. Exp. Res. 10, 393–396.
Pedersen, P.B., Vilmann, P., Bar-Shalom, D., Müllertz, A., Baldursdottir, S., 2013.
Characterization of fasted human gastric ﬂuid for relevant rheological
parameters and gastric lipase activities. Eur. J. Pharm. Biopharm. 85, 958–965.
Pedersen, S.B., 1994. Biopharmaceutical aspects of tolfenamic acid. Pharmacol.
Toxicol. 75 (Supplement 2), 22–32.
Pentikäinen, P.J., Neuvonen, P.J., Backman, C., 1981. Human pharmacokinetics of
tolfenamic acid, a new anti-inﬂammatory agent. Eur. J. Clin. Pharmacol. 19,
359–365.Persson, E.M., Gustafsson, A.S., Carlsson, A.S., Nilsson, R.G., Knutson, L., Forsell, P.,
Hanisch, G., Lennernäs, H., Abrahamsson, B., 2005. The effects of food on the
dissolution of poorly soluble drugs in human and in model small intestinal
ﬂuids. Pharm. Res. 22, 2141–2151.
Persson, L.C., Porter, C.J.H., Charman, W.N., Bergström, C.A.S., 2013. Computational
prediction of drug solubility in lipid based formulation excipients. Pharm. Res.
30, 3225–3237.
Psachoulias, D., Vertzoni, M., Goumas, K., Kalioras, V., Beato, S., Butler, J., Reppas, C.,
2011. Precipitation in and supersaturation of contents of the upper small
intestine after administration of two weak bases to fasted adults. Pharm. Res.
28, 3145–3158.
Roberts, M., Cespi, M., Ford, J.L., Dyas, A.M., Downing, J., Martini, L.G., Crowley, P.J.,
2007. Inﬂuence of ethanol on aspirin release from hypromellose matrices. Int. J.
Pharm. 332, 31–37.
Shi, S., Chen, H., Cui, Y., Tang, X., 2009. Formulation, stability and degradation
kinetics of intravenous cinnarizine lipid emulsion. Int. J. Pharm. 373, 147–155.
Sjögren, E., Westergren, J., Grant, I., Hanisch, G., Lindfors, L., Lennernäs, H.,
Abrahamsson, B., Tannergren, C., 2013. In silico predictions of gastrointestinal
drug absorption in pharmaceutical product development: application of the
mechanistic absorption model GI-Sim. Eur. J. Pharm. Sci. 49, 679–698.
Tamassia, V., Corvi, G., Moro, E., Tosolini, G.P., Fuccella, L.M., 1976.
Pharmacokinetics and bioavailability of indoprofen in man. Eur. J. Clin.
Pharmacol. 10, 257–262.
Walden, M., Nicholls, F.A., Smith, K.J., Tucker, G.T., 2007. The effect of ethanol on the
release of opioids from oral prolonged-release preparations. Drug Dev. Ind.
Pharm. 33, 1101–1111.
Weathermon, R., Crabb, D.W., 1999. Alcohol and medication interactions. Alcohol
Res. Health 23, 40–54.
Vertzoni, M., Dressman, J., Butler, J., Hempenstall, J., Reppas, C., 2005. Simulation of
fasting gastric conditions and its importance for the in vivo dissolution of
lipophilic compounds. Eur. J. Pharm. Biopharm. 60, 413–417.
Whitehead, M.I., Townsend, P.T., Gill, D.K., Collins, W.P., Campbell, S., 1980.
Absorption and metabolism of oral progesterone. Br. Med. J. 280, 825–827.
Wright, D.W., Ritchie, J.C., Mullins, R.E., Kellermann, A.L., Denson, D.D., 2005.
Steady-state serum concentrations of progesterone following continuous
intravenous infusion in patients with acute moderate to severe traumatic
brain injury. J. Clin. Pharmacol. 45, 640–648.
Yang, J.W., Higuchi, W.I., Chiang, H.J., Liu, C.L., 2010. A monomer-micelle model for
the formation of simple taurocholate micelles. J. Chin. Chem. Soc. 57, 199–204.
Yu, L.X., Amidon, G.L., 1998. Saturable small intestinal drug absorption in humans:
modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45,
199–203.
Yu, L.X., Amidon, G.L., 1999. A compartmental absorption and transit model for
estimating oral drug absorption. Int. J. Pharm. 186, 119–125.
Yu, L.X., Crison, J.R., Amidon, G.L., 1996. Compartmental transit and dispersion
model analysis of small intestinal transit ﬂow in humans. Int. J. Pharm. 140,
111–118.
